TET emerged out of groundbreaking innovations originating at Cornell University. The technology is de-risked with human clinical data and 3 issued, 4 pending patents. Our device is a miniature, functioning, highly stable molecular machine, capable of performing chemical operations thousands of times faster than antibody assays: a patented “TET nanobot”, consisting of thousands of enzymes tethered to a nanoparticle.